Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo: Recurrent VTE
Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo Recurrent VTE ‐ early, intermediate and long term · people requiring treatment for chronic DVT Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty). Antiplatelet agents for the treatment of deep venous thrombosis (2022) · Cochrane Headline outcomes only | RR 0.65 [0.43, 0.96] | 4 studies · 901 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.